Letrozole, for the Management of Chronic Pelvic Pain Resulting from Endometriosis

Quratulain Qureshi, Muneeba Sadaf, Rukhsana Rukhsana, Rubina Amjad, Anita Dileep, Muhammad Parial Shahani
In: Pakistan Journal of Medical and Health Sciences · 2023 · vol. 17(3) , pp. 526–527 · doi:10.53350/pjmhs2023173526 · W4376650365
article OA: gold CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This study evaluated Letrozole's effectiveness in treating chronic pelvic pain associated with endometriosis, finding it significantly reduced pain scores over six months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-04 · read from full text ⓘ

This cross-sectional study evaluated letrozole for chronic pelvic pain associated with endometriosis in 60 patients at Sandeman Provincial Hospital/BMCH, Quetta, Pakistan, from December 2021 to December 2022. Participants underwent initial diagnostic laparoscopy to diagnose and score endometriosis, then received oral letrozole 2.5 mg for 6 months alongside celecoxib, calcium citrate, norethisterone acetate, and vitamin D, with pain assessed using a visual analogue scale. The mean pain score decreased from 7.12 before treatment to 6.8 after one month (p=0.02) and to 3.3 after six months, with the authors reporting no recurrence of symptoms. This paper is centrally about endometriosis—specifically the effectiveness of letrozole in reducing chronic pelvic pain due to endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background: Letrozole, an aromatase inhibitor that inhibits the final step of the estrogen biosynthesis pathway to prevent estrogen synthesis, has been utilized in a variety of infertile scenarios. A common gynecological pain problem called endometriosis involves tissue that resembles the tissue that typically lines the inner layer of the uterus. It frequently results in fertility issues. According to the trials, the Letrozole medication continues to reduce the severity of persistent pelvic pain. According to reports, Letrozole therapy relieves pelvic pain brought on by endometriosis. Objective: In this study, we evaluated Letroszole's effectiveness in treating chronic pelvic discomfort associated with endometriosis. Study Design: A cross-sectional study Place and Duration: This study was conducted at Sandeman Provincial Hospital (SPH) / BMCH, Quetta Pakistan from December 2021 to December 2022. Methodology: A total of 60 patients with endometriosis were taken in this study. Patients with a past history of treatment for endometriosis with varying degrees of improvement were also included. Data was analyzed on SPSS version 24.0. Before starting the treatment, an initial diagnostic laparoscopy was used to diagnose and score endometriosis. Oral administration of Letrozole 2.5mg, celbex 200mg three times a day, calcium citrate 1000 mg, progestin norethisterone acetate 5 mg, and vitamin D (1000 IU) was given for 6 months Results: The mean age of the participants was30.9years. A total of 26 (43.3%) patients presented with dysmenorrhea. Out of 60 patients, 43 (71.6%) were nulliparous. The mean visual analogue scale which was 7.12 at the start of the therapy, dropped to 6.8 (p-value 0.02) in one month and dropped to 3.3 in six months of the therapy. Conclusion: Letrozole has been shown to be effective in treating pelvic pain related to endometriosis, with notable pain reduction and no recurrence of symptoms. Keywords: Letrozole, Endometriosis, pain score
Full text 2,116 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Background

Letrozole, an aromatase inhibitor that inhibits the final step of the estrogen biosynthesis pathway to prevent estrogen synthesis, has been utilized in a variety of infertile scenarios. A common gynecological pain problem called endometriosis involves tissue that resembles the tissue that typically lines the inner layer of the uterus. It frequently results in fertility issues. According to the trials, the Letrozole medication continues to reduce the severity of persistent pelvic pain. According to reports, Letrozole therapy relieves pelvic pain brought on by endometriosis.

Objective

In this study, we evaluated Letroszole's effectiveness in treating chronic pelvic discomfort associated with endometriosis. Study Design: A cross-sectional study Place and Duration: This study was conducted at Sandeman Provincial Hospital (SPH) / BMCH, Quetta Pakistan from December 2021 to December 2022. Methodology: A total of 60 patients with endometriosis were taken in this study. Patients with a past history of treatment for endometriosis with varying degrees of improvement were also included. Data was analyzed on SPSS version 24.0. Before starting the treatment, an initial diagnostic laparoscopy was used to diagnose and score endometriosis. Oral administration of Letrozole 2.5mg, celbex 200mg three times a day, calcium citrate 1000 mg, progestin norethisterone acetate 5 mg, and vitamin D (1000 IU) was given for 6 months

Results

The mean age of the participants was30.9years. A total of 26 (43.3%) patients presented with dysmenorrhea. Out of 60 patients, 43 (71.6%) were nulliparous. The mean visual analogue scale which was 7.12 at the start of the therapy, dropped to 6.8 (p-value 0.02) in one month and dropped to 3.3 in six months of the therapy.

Conclusion

Letrozole has been shown to be effective in treating pelvic pain related to endometriosis, with notable pain reduction and no recurrence of symptoms.

Keywords

Letrozole, Endometriosis, pain score

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosischronic_pelvic_paindysmenorrhea

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (18)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK